

Patrick Royston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/663291/publications.pdf>

Version: 2024-02-01

48
papers

15,627
citations

201674

27
h-index

197818

49
g-index

51
all docs

51
docs citations

51
times ranked

26322
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple imputation using chained equations: Issues and guidance for practice. <i>Statistics in Medicine</i> , 2011, 30, 377-399.	1.6	6,168
2	Dichotomizing continuous predictors in multiple regression: a bad idea. <i>Statistics in Medicine</i> , 2006, 25, 127-141.	1.6	1,711
3	Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. <i>Statistics in Medicine</i> , 2002, 21, 2175-2197.	1.6	1,062
4	Prognosis and prognostic research: what, why, and how?. <i>BMJ: British Medical Journal</i> , 2009, 338, b375-b375.	2.3	952
5	Prognosis and prognostic research: Developing a prognostic model. <i>BMJ: British Medical Journal</i> , 2009, 338, b604-b604.	2.3	906
6	Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. <i>BMC Medical Research Methodology</i> , 2013, 13, 152.	3.1	605
7	Further Development of Flexible Parametric Models for Survival Analysis. <i>The Stata Journal</i> , 2009, 9, 265-290.	2.2	590
8	The design of simulation studies in medical statistics. <i>Statistics in Medicine</i> , 2006, 25, 4279-4292.	1.6	529
9	A new measure of prognostic separation in survival data. <i>Statistics in Medicine</i> , 2004, 23, 723-748.	1.6	371
10	The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. <i>Statistics in Medicine</i> , 2011, 30, 2409-2421.	1.6	363
11	Explained Variation for Survival Models. <i>The Stata Journal</i> , 2006, 6, 83-96.	2.2	238
12	A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. <i>Statistics in Medicine</i> , 2004, 23, 2509-2525.	1.6	234
13	Reporting methods in studies developing prognostic models in cancer: a review. <i>BMC Medicine</i> , 2010, 8, 20.	5.5	160
14	Reconstructing Time-to-event Data from Published Kaplan-Meier Curves. <i>The Stata Journal</i> , 2017, 17, 786-802.	2.2	157
15	Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. <i>Lancet, The</i> , 2010, 375, 641-648.	13.7	117
16	Simplifying a prognostic model: a simulation study based on clinical data. <i>Statistics in Medicine</i> , 2002, 21, 3803-3822.	1.6	107
17	Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer. <i>Statistics in Medicine</i> , 2004, 23, 907-926.	1.6	101
18	A simulation study of predictive ability measures in a survival model I: Explained variation measures. <i>Statistics in Medicine</i> , 2012, 31, 2627-2643.	1.6	72

#	ARTICLE	IF	CITATIONS
19	Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. <i>BMJ: British Medical Journal</i> , 2017, 357, j2250.	2.3	67
20	Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data. <i>Statistics in Medicine</i> , 2015, 34, 2881-2898.	1.6	51
21	Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated. <i>BMC Medical Research Methodology</i> , 2016, 16, 16.	3.1	51
22	Two Techniques for Investigating Interactions between Treatment and Continuous Covariates in Clinical Trials. <i>The Stata Journal</i> , 2009, 9, 230-251.	2.2	49
23	Visualizing Length of Survival in Time-to-Event Studies: A Complement to Kaplan Meier Plots. <i>Journal of the National Cancer Institute</i> , 2008, 100, 92-97.	6.3	36
24	Reconstructing time-to-event data from published Kaplan-Meier curves. <i>The Stata Journal</i> , 2017, 17, 786-802.	2.2	36
25	A Menu-driven Facility for Complex Sample Size Calculation in Randomized Controlled Trials with a Survival or a Binary Outcome: Update. <i>The Stata Journal</i> , 2005, 5, 123-129.	2.2	31
26	Interaction of treatment with a continuous variable: simulation study of significance level for several methods of analysis. <i>Statistics in Medicine</i> , 2013, 32, 3788-3803.	1.6	30
27	An approach to trial design and analysis in the era of non-proportional hazards of the treatment effect. <i>Trials</i> , 2014, 15, 314.	1.6	29
28	Interaction of treatment with a continuous variable: simulation study of power for several methods of analysis. <i>Statistics in Medicine</i> , 2014, 33, 4695-4708.	1.6	26
29	Prognostic survival model for people diagnosed with invasive cutaneous melanoma. <i>BMC Cancer</i> , 2015, 15, 27.	2.6	22
30	Meta-analysis of non-linear exposure-outcome relationships using individual participant data: A comparison of two methods. <i>Statistics in Medicine</i> , 2019, 38, 326-338.	1.6	22
31	Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data. <i>BMC Medical Research Methodology</i> , 2015, 15, 82.	3.1	21
32	A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome. <i>Trials</i> , 2020, 21, 315.	1.6	21
33	Modelling to extract more information from clinical trials data: On some roles for the bootstrap. <i>Statistics in Medicine</i> , 2007, 26, 4989-5001.	1.6	18
34	Combined test versus logrank/Cox test in 50 randomised trials. <i>Trials</i> , 2019, 20, 172.	1.6	17
35	Estimating the Treatment Effect in a Clinical Trial Using Difference in Restricted Mean Survival Time. <i>The Stata Journal</i> , 2015, 15, 1098-1117.	2.2	15
36	Multivariable fractional polynomial interaction to investigate continuous effect modifiers in a meta-analysis on higher versus lower PEEP for patients with ARDS. <i>BMJ Open</i> , 2016, 6, e011148.	1.9	13

#	ARTICLE	IF	CITATIONS
37	Tools to Simulate Realistic Censored Survival-Time Distributions. <i>The Stata Journal</i> , 2012, 12, 639-654.	2.2	11
38	A Combined Test for a Generalized Treatment Effect in Clinical Trials with a Time-to-event Outcome. <i>The Stata Journal</i> , 2017, 17, 405-421.	2.2	10
39	Mfpa: Extension of mfp Using the ACD Covariate Transformation for Enhanced Parametric Multivariable Modeling. <i>The Stata Journal</i> , 2016, 16, 72-87.	2.2	8
40	Power and sample-size analysis for the Royston&Parmar combined test in clinical trials with a time-to-event outcome. <i>The Stata Journal</i> , 2018, 18, 3-21.	2.2	7
41	Personalized Model to Predict Keratoconus Progression From Demographic, Topographic, and Genetic Data. <i>American Journal of Ophthalmology</i> , 2022, 240, 321-329.	3.3	7
42	A combined test for a generalized treatment effect in clinical trials with a time-to-event outcome. <i>The Stata Journal</i> , 2017, 17, 405-421.	2.2	5
43	Reconstructing Time-to-event Data from Published Kaplan&Meier Curves. <i>The Stata Journal</i> , 2017, 17, 786-802.	2.2	4
44	mfpa: Extension of mfp using the ACD covariate transformation for enhanced parametric multivariable modeling. <i>The Stata Journal</i> , 2016, 16, 72-87.	2.2	4
45	A smooth covariate rank transformation for use in regression models with a sigmoid dose-response function. <i>The Stata Journal</i> , 2014, 14, 329-341.	2.2	3
46	Investigating treatment-effect modification by a continuous covariate in IPD meta-analysis: an approach using fractional polynomials. <i>BMC Medical Research Methodology</i> , 2022, 22, 98.	3.1	3
47	Power and Sample-Size Analysis for the Royston&Parmar Combined Test in Clinical Trials with a Time-to-Event Outcome: Correction and Program Update. <i>The Stata Journal</i> , 2018, 18, 995-996.	2.2	2
48	The extension of total gain (TG) statistic in survival models: properties and applications. <i>BMC Medical Research Methodology</i> , 2015, 15, 50.	3.1	1